[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"autonomic-nervous-system-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:autonomic-nervous-system-disease":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100455558","auricular-vagal-nerve-stimulation-for-hypermobile-ehlers-danlos-syndrome-100455558",false,"NCT05212129","Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome","Hypermobile Ehlers-Danlos Syndrome: Efficacy of Non-invasive Vagal Nerve Stimulation and Effects on Brain-Gut Physiology","Inclusion Criteria:\n\n* Children aged 10-18 years old\n* Children with functional upper GI complaints and clinical suspicion for hEDS or HSD as well as a Beighton score of at least 4\u002F9\n* Children with functional upper GI complaints and clinical suspicion for ANS dysfunction\n* De-identified data from our prior studies (IRB #689519 and IRB #1064187) of patients with functional GI disorders who do NOT meet criteria for hEDS will be used as a comparison group\n* Children who are English-speaking and lack other explanation for symptoms\n* Children willing to participate and consent to this study (for children, have a parent willing to participate)\n\nExclusion Criteria:\n\nA) Exclusion Criteria applying to all participants:\n\n* Medically complex children or those who take a medication or suffer from a disease that can explain symptoms will be excluded from participation in the study.\n* Adult subjects, children or their parents who have significant developmental delay (will be excluded due to difficulties in accurately completing the questionnaires and assessing symptoms)\n* Patients with findings of organic disease such as peptic ulcer disease, H.pylori gastritis, celiac disease, inflammatory bowel disease, allergic disorders, metabolic disorder or any other chronic condition or medication that may cause chronic GI symptoms will be excluded from the study.\n* Patients who are treated with a new drug affecting the central nervous system in the two weeks prior to enrollment will also be excluded.\n* Pregnancy (evaluating MD screens patients as they normally would during a clinic visit (by questioning) and would only perform urine pregnancy test if clinically indicated (absence of menstrual period or other symptoms concerning for pregnancy)\n* Chronic alcohol\u002Fillicit drug use and\u002For smoking.\n\nB) Exclusion Criteria for subjects undergoing pVNS therapy:\n\n* Severe dermatological condition or active infection of external or middle ear\n* Implanted electrical device\n\nC) Exclusion Criteria for subjects undergoing aVNS therapy:\n\n* Hearing impaired\n* Sight impaired without correction\n* Seizure disorder\n\nD) Exclusion Criteria for subjects undergoing gastric motor function sub-study:\n\n* Patients with pacemakers, metal clips used in previous surgery or other device which are not compatible with MRI scanning\n* Claustrophobia or inability to lie still in the scanner\n* Orthodontic braces or permanent retainers\n* Patients who are unable to tolerate noise produced by the MRI\n* Egg allergy or anticipated inability to complete a standardized egg meal\n\nE) Exclusion Criteria for subjects undergoing HepGI Biobank specimen collection sub-study:\n\n* Bleeding disorder for the specific biopsies\n* Recent antibiotic usage for fecal sample\n* Significant anemia or clinical status which will not allow safe blood draw required for blood collection\n* Refusal of blood collection or to provide DNA sample\n* Inability or unwillingness on the individual (or parent\u002Flegal guardian) to provide clinical or family history.","ALL","10 Years","18 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder characterized by hyperextensible skin, joint hypermobility and additional connective tissue manifestations. For unclear reasons, hEDS is associated with many gastrointestinal (GI) and autonomic nervous system (ANS) complaints such as postural orthostatic tachycardia syndrome (POTS). This study will address the clinical relationship between hEDS\u002FHypermobile Spectrum Disorders and autonomic regulation and see if there is a benefit of two forms of non-invasive vagal nerve stimulation therapies to reduce GI symptoms in hEDS and POTS. The study will also investigate plausible effects of these nerve stimulation therapies on gastric function and autonomic signaling.",[27,28,29,30,31],"Functional Gastrointestinal Disorders","Hypermobile Ehlers-Danlos Syndrome","Postural Orthostatic Tachycardia Syndrome","Autonomic Nervous System Disease","Autonomic Nervous System Imbalance","RECRUITING","2026-02-11",{"date":35,"type":36},"2026-02-13","ACTUAL",{"date":38,"type":36},"2021-04-05",{"date":40,"type":21},"2026-12-31",{"name":42,"class":43},"Medical College of Wisconsin","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100598427","phase-2-randomized-controlled-trial-of-treatment-to-optimize-heart-rate-variability-for-persistent-post-concussion-symptoms-100598427","NCT07071350","Randomized Controlled Trial of Treatment to Optimize Heart Rate Variability for Persistent Post-Concussion Symptoms","Inclusion Criteria:\n\n* age 18 or older\n* History of military service\n* Self-Reported hx of 1 or more mild TBI\n* Most recent TBI more than 1 year ago\n* Significant Persistent Post-Concussion Symptom burden (Neurobehavioral Symptom Inventory \\[NSI\\] total score greater than or equal to 20).\n* Current Sleep Difficulties\n* Fluent English\n* Able to provide Informed Consent\n\nExclusion Criteria:\n\n* Any TBI with severity greater than mild (i.e., Moderate or Severe TBI defined as initial injury loss of consciousness (LOC) duration \\>30 minutes, posttraumatic amnesia (PTA) duration \\>24 hours, or traumatic hemorrhage on head computerized tomography (CT) and determined by the study investigator based on information gathered during administration of the study's validated TBI structured interview instrument.\n* Conditions or medications that can affect HRV measurement (pacemaker or an implant that stimulates your heart (e.g., cardioverter-defibrillator or ICD); heart transplant or heart surgery within the last year, including bypass or other surgery, but not including a stent)\n* Hx of stroke\n* Mental conditions that may impede adherence (e.g., dementia, psychotic disorder, panic disorder)",{"count":52,"type":21},148,[54,55],"PHASE2","PHASE3","Many combat veterans (c-Vs), service members (SMs) and civilians with mild traumatic brain injury (mTBI, also termed concussion) suffer from persistent post-concussion symptoms (PPCS) that degrade physical and cognitive well-being and have been linked with early neurodegeneration. PPCS include somatosensory (e.g., headache, disturbed vision), vestibular (e.g., dizzy, clumsy), cognitive (e.g., executive function, memory) and affective symptoms (e.g., sleep disturbance, irritability, depression). A key pathological process that provokes and perpetuates PPCS is autonomic nervous system (ANS) dysfunction such as unremitting sympathetic nervous system activation that also exacerbates other pathology such as inflammation. ANS activity can be readily quantified by measuring heart rate variability (HRV), or the variation in heart rate over time, which serves as a valid index of both physiological and psychological health",[30,58,59,60,61],"Concussive Injury","Mild Traumatic Brain Injury","Post Traumatic Stress Disorder","Persistent Post Concussion Syndrome","2025-09-15",{"date":64,"type":36},"2025-09-17",{"date":66,"type":36},"2025-09-02",{"date":68,"type":21},"2028-09",{"name":70,"class":43},"Virginia Commonwealth University"]